Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Typhoid Vi Polysaccharide Vaccine · 1 trial · 6 indications
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
| Arm | Type | Description |
|---|---|---|
| TF+YF | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine. |
| TF + YF + MenACWY-CRM197 | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine. |
| JE + Rabies | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine. |
| JE + Rab + MenACWY-CRM197 | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine. |
| Rabies | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine. |
| MenACWY-CRM197 (Combined) | ACTIVE_COMPARATOR | Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine. |
| Name | Type | Description |
|---|---|---|
| Typhoid Vi Polysaccharide Vaccine | BIOLOGICAL | One dose of typhoid Vi polysaccharide vaccine. |
| Yellow Fever Vaccine | BIOLOGICAL | One dose of yellow fever vaccine. |
| Japanese Encephalitis Vaccine | BIOLOGICAL | Two doses of Japanese Encephalitis Vaccine. |
| Rabies Vaccine | BIOLOGICAL | Three doses of Rabies vaccine. |
| MenACWY-CRM Vaccine | BIOLOGICAL | One dose of MenACWY-CRM vaccine. |
Inclusion Criteria: Female and male subjects who must be healthy and must be: 1. Between 18 and 60 years of age inclusive and who have given their written informed consent; 2. Available for all visits and telephone calls scheduled for the study; 3. In good health as determined by medical history, ...
Typhoid Vi Polysaccharide Vaccine is an investigational vaccine being studied for use in preventing meningococcal disease, typhoid, yellow fever, rabies, and Japanese encephalitis. It is being evaluated in adults aged 18 years and older. The vaccine is currently in Phase 3 clinical development and is not yet approved.
Typhoid Vi Polysaccharide Vaccine is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity. As of the latest data, the vaccine is in Phase 3 development.
Typhoid Vi Polysaccharide Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 552 participants, to assess its safety and immunogenicity.
Typhoid Vi Polysaccharide Vaccine has one completed Phase 3 trial, NCT01466387. This open-label, randomized, active-controlled study evaluated the safety and immunogenicity of select travel vaccines when administered concomitantly with MenACWY in adults. The trial enrolled 552 participants in Czechia and Germany.
No, Typhoid Vi Polysaccharide Vaccine is not a monoclonal antibody. It is classified as a vaccine, specifically a Vi polysaccharide vaccine. The drug is being developed for infectious disease indications, including meningococcal disease and typhoid.